Guest guest Posted April 29, 2010 Report Share Posted April 29, 2010 New Drugs Summary EASL Page Continues to be Updated Last Update April 29 .. April 14-18, 2010 The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) Vienna Austria , Also View @ J & F Website EASL Round Up ..From NATAP / EASL/Coverage Summary Natural History/ Fibrosis progression in initially mild chronic hepatitis C: 36% with F1 Progress to F3 or cirrhosis - Impact of Sustained Virological Response After Antiviral Treatment in Chronic Hepatitis C Patients on Life Expectancy and Quality-adjusted Life-years - , Boceprevir The drug — developed by Schering-Plough, which merged with Merck in November 2009 — is now in a fully enrolled phase 3 trial. Merck officials expect to file the Food and Drug Administration application later this year, and they hope for approval in 2011. ,Side Effects: Most common adverse events reported in the boceprevir were fatigue, anemia, nausea, rash, and headache. The incidence of skin adverse events (rash or pruritus) observed in the boceprevir was similar to that seen in PEGINTRON and REBETOL ,Safety Results From The " Long-term Outcomes Following Combination Treatment with Boceprevir plus PegIntron/Ribavirin (P/R) in Patients with Chronic Hepatitis C, Genotype 1 (CHC-G1) -" .. The Studies ,HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse .. High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy - Results From HCV Sprint-1 -Response-Guided Therapy for Boceprevir Combination Treatment? Results from HCV SPRINT-1 - ..Long-term Outcomes Following Combination Treatment with Boceprevir plus PegIntron/Ribavirin (P/R) in Patients with Chronic Hepatitis C, Genotype 1 (CHC-G1) - ..Telaprevir ..Telaprevir combined with older anti-viral treatments peginterferon and ribavirin cured 93 percent to 100 percent of patients with hepatitis C genotype 1 after 48 weeks of treatment, according to Vertex Pharmaceuticals and & . The results were unveiled at the European Association for the Study of the Liver in Vienna. ..Vertex Pharmaceuticals Inc said it will begin the process this summer of seeking U.S. approval for telaprevir, its eagerly anticipated experimental treatment for hepatitis C. Analysts expect the drug to be approved in 2011 and provide a significant advance in the treatment of the serious liver disease, which is the biggest cause of liver transplants in the United States.. Side Effects From The April 30 2009 Study: Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. .. Both rash and pruritus were frequently reported in this study, but they did not always occur in combination. Severe rash occurred in approximately 5% of patients treated with telaprevir. Both rash and pruritus regressed after withdrawal of telaprevir and administration of appropriate therapy, including topical treatments for symptoms and corticosteroids (in some cases, systemic corticosteroids). Patients receiving telaprevir should be clinically monitored for dermatologic reactions and treated appropriately. The optimal management of rash and its effect on treatment adherence and efficacy requires further investigation. Decreased hemoglobin levels were also more frequent among the patients receiving telaprevir than among those in the control group, though the condition was not often a cause of treatment discontinuation. .. The Studies Telaprevir or Boceprevir Telaprevir-Based Regimens in Study 107 Telaprevir the right combination Prior Non-responders Achieve Treatment Success with Telaprevir plus Pegylated Interferon and Ribavirin EASL/ More On Telaprevir; Genotype 1 Achieve early response can treat within 6 months On-Treatment Response-Guided Therapy with Telaprevir q8h or q12h Combined with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C (Study C208) - TELAPREVIR NAÃVE Geno 2 & 3/ FINAL RESULTS OF STUDY C209 , VX-222 ,Vertex/In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity. Dosing with VX-222 for three days resulted in a greater than 3 log10 reduction in HCV RNA across all four of the VX-222 dosing groups. The results from this trial support the Phase 2 proof-of-concept clinical trial of VX-222 dosed in combination with Vertex's lead investigational HCV protease inhibitor telaprevir, which is expected to complete enrollment in the second quarter of 2010. Vertex retains worldwide rights to VX-222. ..Side Effects : No serious adverse events or treatment discontinuations were reported in the Phase 1b trial. / The Studies ,..Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial ..VX-222 Vertex NNRTI Polymerase Inhibitor 3 Days Monotherapy . SCY-635 ...Scynexis Inc., of Research Triangle Park, N.C., reported results from two studies of SCY-635, an oral, cyclophilin inhibitor designed to treat hepatitis C virus infection. Data from an in vitro study showed that, unlike other cyclophilin inhibitors, SCY-635 is not associated with an increased risk of hyperbilirubinemia in 15-day clinical studies. A second presentation outlined the effects of the drug in in vitro studies on collagen production and fibrosis, suggesting that it might have an antifibrotic effect independent of demonstrated anti-HCV activity. SCY-635 is set to enter Phase II in the second half of this year. . , The Studies .... ,Results from two separate studies of SCY-635-a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C ..AVL181 AVL-192 ..Avila Therapeutics Inc., of Waltham, Mass., presented results of preclinical studies on two of its hepatitis C virus protease inhibitors, AVL-181 and AVL-192. The inhibitors achieved sustained, irreversible silencing of HCV protease. Preclinical data have demonstrated that each drug achieves high potency and selectivity and also effectively inhibits drug-resistant mutations of HCV protease. In addition, AVL-192 has shown unusually high potency by demonstrating the ability to clear replicon cells as a monotherapy in vitro.The company said they have the potential as best-in-class, pan-genotype HCV therapeutics. / The Studies , /Two Novel, Orally-Available Protease Inhibitors, AVL-181 And AVL-192, For Hepatitis C Infection At EASL Meeting ,BMS-790052 ..,An experimental oral drug is showing early promise for the treatment of chronic hepatitis C virus (HCV) infection, a study shows.In preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.The research is so early that the drug hasn't been named. It is known as BMS-790052. / The Studies /EASL/ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN ...Once-daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-alpha-2a And Ribavirin Produces High Rates Of Extended Rapid Virologic Response In Treatment-naïve HCV-genotype 1 Subjects: Phase 2a Trial - Bristol-Myers Squibb Study AI444014 ..BMS-790052/ NEW Bristol compound potent against HCV/Fewer Side Effects ..BMS NS5A HCV Inhibitor - chemical genetics discovery process in Nature jnl - pdf attached -.. Locteron ...Biolex Therapeutics Inc., of Pittsboro, N.C., said that EMPOWER, a prospectively designed analysis of results from two Phase IIb trials of Locteron, showed the 480 mcg dose demonstrated viral kinetics and response rates that were comparable to the PEG-Intron control, while also achieving a 57 percent reduction in flu-like adverse events. The 133 patients in the EMPOWER study were enrolled in two contributing Phase IIb trials. .. The Studies ... Locteron, controlled-release interferon alpha 2b, 3 studies at EASL 2010 Vienna - 3 company press releases ..EASL Locteron Show 65% Reduction In Flu-Like Side Effects With Comparable Efficacy In Hepatitis C ,AST-120 ..Ocera Therapeutics Inc., of San Diego, presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients, showing that a majority of patients have a neurocognitive deficit and suffer from mild hepatic encephalopathy. Those data came from an ongoing Phase IIb trial of AST-120 (spherical carbon adsorbent). Ocera also presented data demonstrating the potential of AST-120 to lower ammonia and reduce brain edema in a preclinical model of cirrhosis. / The Studies ...EASL/AST-120 Treatment of mild hepatic encephalopathy (MHE). IDX320 ...Idenix Pharmaceuticals Inc., of Cambridge, Mass., reported in vitro data for hepatitis C virus protease inhibitor IDX320, demonstrating potent and selective antiviral activity in multiple genotypes of the virus. Additional data showed that a combination of three Idenix drug candidates, including IDX320, with different mechanisms of action produced strong synergy in vitro. / The Studies ...IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C ..In Vitro Antiviral Activity of IDX320, a Novel and Potent Macrocyclic HCV Protease Inhibitor - ,Triple Combinations of Direct-Acting Antiviral Agents Demonstrate Robust Anti-HCV Activity In Vitro .. IDX320Nitazoxanide ..,Adding nitazoxanide (Alinia, Romark Laboratories) to standard therapy helped boost sustained virologic response (SVR) rates for some hepatitis C virus (HCV) genotype 1 patients who previously failed to respond to standard therapy alone, researchers report.But the addition of the drug led to only "modest" success, they said in a presentation here at the European Association for the Study of the Liver 45th Annual Meeting. / The Studies .. ."Modest" Results With Nitazoxanide for HCV Genotype 1 Nonresponders ..Romark Announces Data From Clinical Trial Of Nitazoxanide In Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C ..Nitazoxanide + Peg/Rbv in Nonresponders ..Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Week 12 Sustained Virologic Response Rate - ..ANA598 ..ANA598 is wholly owned by Anadys, which has completed three Phase I clinical studies of the drug demonstrating potent antiviral activity and good tolerability.The preliminary analysis of results through eight weeks also showed that ANA598 400 mg twice daily dose plus SOC was well tolerated, with an adverse event profile comparable to SOC alone, the company noted, adding that at 200 mg twice daily dose of the drug, no patient experienced viral breakthrough, which is an increase in viral load while on antiviral treatment.Side Effects:Through eight weeks, 32% of patients receiving ANA598 400 mg twice daily plus SOC developed rash, compared to 21% of patients at week four and 41% at week 12 for patients who received ANA598 200 mg twice daily plus SOC, Anadys said in a statement. , The Studies , ...72% of Patients Receiving ANA598 in Phase II Combination Study With Interferon and Ribavirin Achieve Undetectable Levels of Virus at Week Eight , ANA598 HCV Polymerase Inhititor Safety & Activity + Peg/Rbv in Genotype 1 .., IDX184 IDX184 50 and 100 mg cohorts in combination with pegylated interferon and ribavirin (PegIFN/RBV) demonstrated a favorable safety profile and potent antiviral activity at 14 days-- Fifty percent of subjects receiving a total daily dose of 100 mg IDX184 achieved undetectable virus levels by Day 14-- Study continuing with enrollment of 150 mg cohort"We are very encouraged by these interim data for IDX184 combined with pegylated interferon and ribavirin as the viral load reductions for the 100 mg cohorts are on par with the first-generation nucleoside in development but at a fraction of the dose," said Mayers, M.D., Idenix's executive vice president and chief medical officer. "We are currently enrolling the 150 mg once-daily dose cohort and look forward to reporting full data later this year. We believe that with the favorable antiviral activity, safety and resistance profile seen to date, IDX184 could be a potential component of future direct-acting antiviral combination regimens."Side Effects : The side effect profile of the three-drug combination was consistent with the known side effect profile of PegIFN/RBV alone. The most common adverse events reported were fatigue, myalgia, headache and nausea. No virologic breakthrough was observed during treatment with IDX184 in combination with PegIFN/RBV. .. The Studies ..IDX184 nucleoside polymerase From Interim Analysis of Phase IIa Hepatitis C Study Antiviral Activity, Pharmacokinetics & Safety of IDX184 in Combination with Peg/Rbv in Treatment Na�ve Genotype 1 - ,. ABT-333 ,, ABT-333 is a novel non-nucleoside NS5B polymerase inhibitor being developed for the treatment of HCV genotype 1 infection. Abbott Laboratories and partner Enanta Pharmaceuticals said they will evaluate three potential hepatitis C drugs in Phase 2 clinical trials. The drug candidates include ABT-450, which was discovered through the partnership. Also moving into midstage development are ABT-333 and ABT-072, which were both discovered by Abbott.The midstage studies will focus on safety, tolerability, and antiviral activity. ,. Side Effects :ABT-333 was safe and well tolerated in single and multiple ascending doses up to the highest doses studied in healthy volunteers: 2000 mg in single doses and 1600 mg BID in multiple doses .. The Studies / .. Pharmacokinetics of the HCV Polymerase Inhibitor ABT-333 in US and Japanese Healthy Volunteers , Resistance Profile Of ABT-333 And Relationship To Viral Load Decrease In Patients Treated In Combination With Peg-interferon And Ribavirin For 28 Days. - .. ABT-333 .., Exposure-Viral Response Analyses of the Non-nucleoside Polymerase Inhibitor ABT-333, Following Monotherapy and ABT-333 Plus Pegylated Interferon and Ribavirin Therapy -,A .... .. PPI-461 Presidio Pharmaceuticals, Inc. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.“PPI-461 exhibited potent and selective activity against all HCV genotypes in the in vitro replicon system, showed good oral bioavailability in multiple animal species and was well tolerated in a variety of animal studies. PPI-461 exhibited elevated liver concentrations relative to plasma levels that may be advantageous for lower dose regimens and a pharmacokinetic profile that indicated the potential for once daily dosing in humans .. The Studies , First-in-Human Clinical Trial of PPI-461, an Investigational NS5A Inhibitor for HCV ..EASL/PPI-461, A POTENT AND SELECTIVE HCV NS5A INHIBITOR WITH ACTIVITY AGAINST ALL HCV GENOTYPES Mk-5172 Resistance Merck is trying to make itself a major player in the hepatitis market. The Big Pharma inherited Schering Plough’s boceprevir, which is in late-stage trials and is expected to face review by the FDA before the end of the year. The company also markets the combined treatment regimen of Pegintron and Rebetol. Merck has vaniprevir in mid-stage development and MK-5172 in early developmentMK-5172 is a novel NS3/4a protease inhibitor with an attractive preclinical profile including high in vitro potency, significant liver exposure upon oral dosing, and potent inhibitory activity against known viral variants that are resistant to other protease inhibitors in development. MK-5172 has also demonstrated antiviral efficacy in a chimpanzee model of chronic HCV infection.Clinical studies with MK-5172 are currently in progress. .. The Studies.MK-5172, the 1st HCV Protease Inibitor with Potent Acyivity Against Resistance Mutations In Vitro - EASL MK-5172: A NOVEL HCV NS3/4A PROTEASE INHIBITOR Merck HCV Protease Inhibitor For Resistance TMC435 Tibotec's investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 demonstrated good antiviral activity and appeared to be safe and generally well-tolerated in a Phase 1 placebo-controlled clinical trial, according to a report in the March 2010 Gastroenterology. Side Effects : Generally well-tolerated .. The Studies ..TMC435 & Drug Interactions: Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers - Combination of TMC435 with two novel NS5B inhibitors increases anti-HCV activity and results in a higher genetic barrier in vitro - HCV Inhibitor TMC435 RG7128 The Pharmasset investigational nucleoside analog hepatitis C virus (HCV) polymerase inhibitor RG7128, used in combination with pegylated interferon plus ribavirin, increased sustained virological response (SVR) rates among genotype 2 and 3 chronic hepatitis C patients who did not respond to a prior course of standard therapySide Effects : Headache and fatigue were the most frequently reported adverse events in patients who received active RG7128 plus Pegasys plus Copegus,Pharmasset, Inc.:The 28-day clinical trial data on HCV polymerase inhibitor RG7128 in genotype 2/3 patients; .. The Studies .. ,Sustained Virologic Response following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV Genotype 2/3 prior non-responders - ..EARLY ON-TREATMENT RESPONSES DURING PEGYLATED INTERFERON PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1) ,In vitro data on new nucleotide analogs PSI-7977 and PSI-938.Genotype 2/3 Pharmasset To Present New Data On RG7128 And PSI-7977 At The EASL Conference ..Combination of two complementary nucleotide analogues, PSI-7977 and PSI-938, effectively clears wild type and NS5b: S282T HCV replicons - Comparison with combinations of other antiviral compounds - ..RG7227 ITMN-191 ,InterMune (ITMN) announced top-line results from the planned Week 12 interim analysis of the Phase 2b randomized, partially-blind study evaluating the hepatitis C virus (HCV) protease inhibitor danoprevir (also known as RG7227 and ITMN-191Results from the study showed the drug, danoprevir, which is being co-developed with Roche , delivered virologic response in 88 percent of patients treated under a 300 mg dosage for 12 weeks, InterMune said. The safety and antiviral activity of danoprevir is expected to be further evaluated in a Phase 2b study of danoprevir in combination with low doses of ritonavir and the current standard of care, and is also under clinical investigation in combination with the NS5B nucleoside polymerase inhibitor RG7128 in the INFORM clinical development programSide Effects: The ritonavir-boosted combination showed a favorable safety and tolerability profile. The most commonly reported adverse events (AEs) were headache, nausea and diarrhea and these had a similar incidence to previously reported studies of danoprevir in combination with standard of care (SOC). .. The Studies ...RG7227 and ITMN-191/InterMune gives promising mid-stage data on hep C drug ..IMPACT OF LOW-DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF DANOPREVIR (RG7227; ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE ..InterMune Reports Virologic Response of Ritonavir-Boosted Danoprevir (RG7227/ITMN-191) in Patients with Chronic Hepatitis C ..Filiburvir ..The Pfizer drug Filiburvir or FLV in combination with pegIFN and RBV for 4 weeks was well tolerated and resulted in higher on-treatment virologic response rates relative to pegIFN/RBV alone. However, longer durations of triple therapy will be required to assess the potential for reduced rates of relapse and improvement in SVR rates. A study evaluating 24 weeks of FLV/pegIFN/RBV is currently underway ..Side Effects: Well-tolerated no serious adverse events reported .. The Studies ,Virologic Response Rates Following 4 Weeks of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Chronically-Infected HCV Genotype-1 Patients ,Genotypic Characterisation of Filibuvir Resistance in Patients Receiving Four Weeks Co-administration of Filibuvir with pegIFN/RBV(12 Week Analysis). Exposure-response Relationship of Filibuvir in HCV-infected Patients: Application to Dose Selection for Combination Therapy ..ACH-1625 ..Achillion Pharmaceuticals ,Realizing that some of its competitors are farther ahead with their protease inhibitor development -- like Vertex's (VRTX) telaprevir and Merck's (MRK) boceprevir -- Achillion expects that ACH-1625's demonstrated potency and safety will be enough to "differentiate it from the pack and push it ahead of competition once it hits the market."So far, says Kishbauch, ACH-1625 has shown four significant characteristics over competitors "that could make it a best in class." First, he says, is "its potency in reducing the [amount of virus] is at the top end vs. any of the other similar drugs discovered. Second, other first-generation protease inhibitors have safey and tolerability concerns such as rashes and anemia. ACH-1625's safety and tolerability profile is so far among the cleanest of any the drugs in development."Third, ACH-1625 appears likely to be dosable at once-a-day, while first-generation drugs will need to be dosed every 8 to 12 hours. Fourth, one of the surprisingly serendipitous finding is its durability, meaning that once you discontinue dosing, the drug continues to have antiviral effect up to seven days after discontinuation of dosing. Other drugs return to baseline virus levels after 24-48 hours. This is important, in particular, with missed doses."Side Effects: ACH-1625's safety and tolerability profile is so far among the cleanest of any the drugs in development .. The Studies .. ACH-1625 Achillion's 'Very Promising' New Drug for Hepatitis C ..BI 201335 ..Boehringer Ingelheim's investigational NS3/4A hepatitis C virus (HCV) protease inhibitor BI 201355, in combination with pegylated interferon plus ribavirin, produced rapid and early virological response in patients with HCV genotype 1 who did not achieve sustained response with a prior course of therapy, according to a late-breaker oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last week in Vienna.Side Effects: Skin rash was a common side effect, however, affecting 30%-60% of patients. , The Studies ..,Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335 ..Boerhinger Ingelheim's BI-201335 (let's call it '335 for short) seems to be the telaprevir competitor ..Drug BI 207127 ..Boerhinger Ingelheim Drug BI 207127 works by preventing the Hepatitis C virus from replicating by inhibiting the HCV polymeraseSide Effect : The drug was generally well-tolerated. A minor rash and redness of skin was reported but managed effectively .. The Studies ,.4 week therapy with the non-nucleosidic polymerase inhibitor BI 207127 in combination with peginterferon alfa2A and ribavirin in treatment naïve and treatment experienced chronic HCV GT1 patients , GS9450 .. ,STUDY STOPPED: Gilead stops Phase II test of GS 9450 hepatitis drug test after ‘adverse events’ ,Potential Of Gs-9450 As New Treatment Option For Steatohepatitis Supported By New Phase II Study .. ..Peginterferon/Ribavirin ..The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 percent), arthralgia (22 percent), depression (20 percent), pruritus (19 percent) and dermatitis (16 percent). ..Pegasys vs Pegintron, Baseline characteristics and on-treatment predictors of responses from real-world patient cohorts: interim results of the multinational PROPHESYS cohorts - ..Improved Inflammatory Activity With Low-Dose PegIntron (PEG) Maintenance Therapy in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program - ..COMPLETELY INDIVIDUALIZED TREATMENT DURATIONS (24, 30, 36, 42, 48, 60 OR 72 WEEKS) WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS (INDIV-2 STUDY) ..RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B +RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B +RIBAViRIN IN TREATMENT-NAÃVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A) ..Slow Responders Benefit From 72 Weeks Peg/Rbv - Predicting Treatment Outcome Among Slow Responders: A Retrospective Analysis of the SUCCESS Study ..Q2week Controlled Release Interferon Alpha2b + Ribavrin Reduces Flu-like Symptoms >50% And Provides Equivalent Efficacy In Comparison To Weekly Pegylated Interferon Alpha2b + Ribavirin In Treatment-naïve Genotype-1 Chronic Hepatitis C: Results From EMPOWER, A Randomized Open-label 12-week Comparison In 133 Patients ..Predictors of relapse among patients treated with standard- or induction-dose peginterferon alfa-2a (40KD) combined with standard- or higher-dose ribavirin in difficult-to-cure patients - ..High Dose Pegasys/rbv can improve SVR: Impact of higher doses of peginterferon alfa-2a and ribavirin on RVR, cEVR and SVR in HCV G1 patients with viral loads ≥400 000 IU/mL weighing ≥85 kg ..Metabolic Syndrome (MS) [glucose/diabetes] Is a Negative Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: Results From the IDEAL Study - ,EASL/Vitamin D to conventional Peg/RBV therapy for naïve, genotype 1 patients with chronic infection significantly improve SVR... Additional Topics .. The Studies ....EASL/Dark Chocolate and Cirrhosis ..EASL/SILIBININ AS A RESCUE TREATMENT FOR HCV ..EASL/Vitamin D to conventional Peg/RBV therapy for naïve, genotype 1 patients with chronic infection significantly improve SVR. ..EASL New Data on Hepatitis B and C Pathogenesis and TreatmentEASL/Fatty liver disease/ High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis ..Metabolic Syndrome (MS) [glucose/diabetes] Is a Negative Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: Results From the IDEAL Study - Genetic signatures provide new direction in liver cancer http://Hepatitis Cnewdrugs.blogspot.com/2010/04/new-drugs-summary-easl.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.